CORDIS
EU research results

CORDIS

English EN

Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors

Objective

Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million received radiotherapy. In the long-term, potentially 20% of those suffering with mild to severe side-effects (~1.4 million) might benefit from alleviation of symptoms, with resulting reductions in the cost of care in the EU.
REQUITE aims to develop validated clinical models and incorporate biomarkers to identify before treatment cancer patients at risk of side-effects and use the models to design interventional trials aimed at reducing side-effects and improving QoL in cancer survivors who underwent radiotherapy.
REQUITE will:
1. carry out a multi-centre, longitudinal, observational study to collect standardised data and samples in breast, prostate and lung cancer patients;
2. validate biomarkers with published evidence of predictive value;
3. replicate published clinical models and incorporate replicated biomarkers to create validated predictive algorithms;
4. use the prospectively validated models and biomarkers to design interventional trial protocols aiming to reduce side-effects and improve QoL in high-risk patients.
REQUITE builds on collaborations with a proven history of data sharing, enlarged to a consortium with expertise in patient recruitment, knowledge management, biomarker testing and predictive model development. SME involvement for biomarker assays will facilitate future clinical implementation and commercial exploitation. The outcome of this project will be validated predictive models for three common cancers and trial protocols using the models to investigate interventions aimed at reducing long-term side-effects and improving the QoL of cancer survivors.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE UNIVERSITY OF MANCHESTER

Address

Oxford Road
M13 9pl Manchester

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 959 166,26

Administrative Contact

Claire Faichnie (Ms.)

Participants (15)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE MONTPELLIER I.

France

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany

EU Contribution

€ 737 782,50

UNIVERSITEIT GENT

Belgium

EU Contribution

€ 506 305,20

UNIVERSITY OF LEICESTER

United Kingdom

EU Contribution

€ 931 631

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 600 728,04

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 66 592

UNIVERSITE DE MONTPELLIER

France

EU Contribution

€ 119 307,60

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 187 088,80

FUNDACION PUBLICA GALEGA DE MEDICINA XENOMICA

Spain

EU Contribution

€ 304 240

THE CHRISTIE NHS FOUNDATION TRUST

United Kingdom

EU Contribution

€ 189 652

Source Bioscience plc

United Kingdom

EU Contribution

€ 634 720

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

United States

EU Contribution

€ 84 015

STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC

Netherlands

EU Contribution

€ 237 800

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 123 840

INSTITUT REGIONAL DU CANCER DE MONTPELLIER

France

EU Contribution

€ 314 539,60

Project information

Grant agreement ID: 601826

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 820 380,07

  • EU contribution

    € 5 997 408

Coordinated by:

THE UNIVERSITY OF MANCHESTER

United Kingdom